SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Deciphera Pharmaceuticals, Inc. (DCPH) , 前瞻盈利收益率 2.28%.
本页证实的标准:
- VALUE (50/100, 部分通过) — 信号不一 — 部分估值指标有利，其他则偏高。
- 前瞻市盈率 43.8
- 分析师共识目标价 $26.32 (+2.9% 上行空间) — 预期温和上涨。
SharesGrow 综合评分： 51/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
~
价值
50/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — DCPH
估值倍数
P/E (TTM)0.0
前瞻 P/E43.8
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率13.32
EV/EBITDA0.0
每股数据
EPS (TTM)$-2.29
前瞻 EPS（预估）$0.58
每股账面价值$0.00
每股营收$1.92
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield2.28%
股息收益率0.00%
分析师目标价$26.32 (+2.9%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2015 |
$-0.95 |
$0.00 |
$-19.82M |
- |
| 2016 |
$-1.24 |
$0.00 |
$-25.94M |
- |
| 2017 |
$-2.99 |
$0.00 |
$-50.28M |
- |
| 2018 |
$-2.82 |
$0.00 |
$-99.85M |
- |
| 2019 |
$-4.47 |
$25M |
$-191.49M |
-766% |
| 2020 |
$-4.78 |
$42.09M |
$-266.49M |
-633.2% |
| 2021 |
$-5.11 |
$96.15M |
$-296.84M |
-308.7% |
| 2022 |
$-2.37 |
$134.04M |
$-178.93M |
-133.5% |
| 2023 |
$-2.29 |
$163.36M |
$-194.94M |
-119.3% |
